Genexis Biotech, a cutting-edge biotechnology company, is spearheading a groundbreaking approach to protein production by eliminating the need for foetal bovine serum (FBS). With the challenges posed by the Covid-19 pandemic highlighting the fragility of global FBS supplies, Genexis Biotech’s innovation couldn’t come at a better time. FBS, traditionally sourced from bovine foetuses, is crucial for cell culture media used in various biopharmaceutical applications, including Covid-19 diagnostic tools and vaccines.
Genexis Biotech: Revolutionizing Protein Production with Animal-Free Technology
-
Flamengo and PSG have faced each other three times; check out their record
-
Indonesia Open Footgolf Tournament: Comedian Oki Rengga Admits Addiction, Wants to Become a Professional Athlete
-
Shameful Incident in Punjab! Landlord Rolls Tenant’s Daughter
-
Virgil van Dijk Expresses Desire for Mohamed Salah to Stay at Liverpool
Deixe um comentário